Who is sponsoring NCT02551003?

NCT02551003 is sponsored by Children's Hospital of Fudan University.

What drugs are being tested in NCT02551003?

Interventions in NCT02551003: Autologous cord blood, Hypothermia.

What condition does NCT02551003 study?

NCT02551003 studies Hypoxic Ischemic Encephalopathy, Cerebral Infarction.

Is NCT02551003 still recruiting?

NCT02551003 is currently withdrawn. Last updated 29 December 2023.

Last reviewed 2023-12-29 · How we verify

NCT02551003

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy

Withdrawn Phase 1, PHASE2 Last updated 29 December 2023

What this trial tests

Phase 1, PHASE2 trial testing Autologous cord blood in Hypoxic Ischemic Encephalopathy. Withdrawn.

Timeline

8 September 2015

Primary endpoint
30 December 2016

30 December 2016

Quick facts

Lead sponsor	Children's Hospital of Fudan University
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Start date	8 September 2015
Primary completion	30 December 2016
Estimated completion	30 December 2016
Sites	1 location across China

Drugs / interventions tested

Autologous cord blood — full drug profile →
Hypothermia

Conditions studied

Hypoxic Ischemic Encephalopathy — all drugs for Hypoxic Ischemic Encephalopathy →
Cerebral Infarction — all drugs for Cerebral Infarction →

Sponsor

Children's Hospital of Fudan University

Who can join

Under 24 Hours, any sex, with Hypoxic Ischemic Encephalopathy or Cerebral Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examines the effect of cord blood in the treatment of newborn infants with neonatal encephalopathy in combination with hypothermia, which is the standard treatment for this condition. The hypothesis is that the cord blood + hypothermia combination will produce better neuroprotection than the standard treatment of hypothermia alone.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy.
Ranjan AK, Gulati A. · · 2023 · cited 41× · PMID 37892791 · DOI 10.3390/jcm12206653
Emergent Prophylactic, Reparative and Restorative Brain Interventions for Infants Born Preterm With Cerebral Palsy.
Finch-Edmondson M, Morgan C, Hunt RW, Novak I. · · 2019 · cited 29× · PMID 30745876 · DOI 10.3389/fphys.2019.00015
Neonatal asphyxia as an inflammatory disease: Reactive oxygen species and cytokines.
Okazaki K, Nakamura S, Koyano K, Konishi Y, et al · · 2023 · cited 16× · PMID 36776908 · DOI 10.3389/fped.2023.1070743
Cell-based treatment for perinatal hypoxic-ischemic encephalopathy.
Park YJ, Borlongan CV, Dezawa M. · · 2021 · cited 16× · PMID 34084971 · DOI 10.4103/bc.bc_7_21
Autologous cord blood in children with cerebral palsy: a review.
Boruczkowski D, Pujal JM, Zdolińska-Malinowska I. · · 2019 · cited 14× · PMID 31100943 · DOI 10.3390/ijms20102433
Neonatal encephalopathy due to suspected hypoxic ischemic encephalopathy: pathophysiology, current, and emerging treatments.
Babbo CC, Mellet J, van Rensburg J, Pillay S, et al · · 2024 · cited 13× · PMID 39237728 · DOI 10.1007/s12519-024-00836-9
Hypothermia combined with neuroprotective adjuvants shortens the duration of hospitalization in infants with hypoxic ischemic encephalopathy: Meta-analysis.
Ovcjak A, Pontello R, Miller SP, Sun HS, et al · · 2022 · cited 13× · PMID 36686686 · DOI 10.3389/fphar.2022.1037131
Rationale for the Use of Cord Blood in Hypoxic-Ischaemic Encephalopathy.
Zdolińska-Malinowska I, Boruczkowski D, Hołowaty D, Krajewski P, et al · · 2022 · cited 5× · PMID 35599846 · DOI 10.1155/2022/9125460

Verify or expand the search:

Other recruiting trials for Hypoxic Ischemic Encephalopathy

Currently open trials in the same condition.

NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
NCT06762795 — The HIEnome Study: Genome Sequencing for Perinatal HIE · NA · recruiting

Other Children's Hospital of Fudan University trials

Trials by the same sponsor.

NCT04955821 — Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS · not yet recruiting
NCT05862688 — A Cohort Study on Anti-microbial Stewardship in PICU · not yet recruiting
NCT05595239 — Blood Purification in Septic Children · NA · not yet recruiting
NCT07325903 — Research of Integrated Traditional Chinese and Western Medicine on Precocious Puberty · EARLY_PHASE1 · not yet recruiting
NCT07141615 — Clinical Observation of Qingwei Huazhuo Decoction (Product: Jinsaiyu) in Improving Children With Precocious Puberty of P · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02551003 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Hospital of Fudan University
Last refreshed: 29 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02551003.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing